Who are Persantine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brilinta, Brilinta, Integrilin, Aggrastat.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dipyridamole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Persantine — Competitive Intelligence Brief

Persantine (DIPYRIDAMOLE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platelet Aggregation Inhibitor [EPC]. Area: Cardiovascular.

marketed Platelet Aggregation Inhibitor [EPC] Equilibrative nucleoside transporter 1 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Persantine (DIPYRIDAMOLE) — Boehringer Ingelheim. Persantine works by inhibiting platelet activation and aggregation by blocking the equilibrative nucleoside transporter 1.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Persantine TARGET	DIPYRIDAMOLE	Boehringer Ingelheim	marketed	Platelet Aggregation Inhibitor [EPC]	Equilibrative nucleoside transporter 1	1961-01-01
Brilinta	ticagrelor	AstraZeneca	marketed	P2Y12 Platelet Inhibitor [EPC]	Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
Brilinta	Brilinta	AstraZeneca	marketed		Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12
Integrilin	EPTIFIBATIDE	Merck & Co.	marketed	Platelet Aggregation Inhibitor [EPC]	Integrin alpha-IIb/beta-3	1998-01-01
Aggrastat	TIROFIBAN	Medicure	marketed	Platelet Aggregation Inhibitor	Integrin alpha-IIb/beta-3	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2030-04-17 — Brilinta · 8425934 · Formulation · US
2030-10-17 — Brilinta · 8425934*PED · Compound · US
2036-01-27 — Brilinta · 10300065 · Method of Use · US
2036-07-27 — Brilinta · 10300065*PED · Compound · US

Sponsor landscape (Platelet Aggregation Inhibitor [EPC] class)

Boehringer Ingelheim · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Persantine — Competitive Intelligence Brief. https://druglandscape.com/ci/dipyridamole. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab